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Abstract. Purpose: to study the potential utility of 1-thio-D-glucose labeled with 99mTc for cancer imaging in laboratory 
animals. Materials and method: the study was carried out in cell cultures of normal CHO (Chinese hamster ovary cells 
CHO) and malignant tissues MCF-7 (human breast adenocarcinoma MCF-7). To evaluate the uptake of 99mTc-1-thio-D-
glucose in normal and tumor tissue cells, 25 MBq of 1-thio-D-glucose labeled with 99mTc was added to the vials with 
3 million cells and incubated for 30 min at room temperature. After centrifugation of the vials with cells, the supernatant 
was removed. The radioactivity in vials with normal and tumor cells was then measured. In addition, the study included 
40 mice of C57B1/6j lines with tumor lesion of the right femur. For neoplastic lesions, Lewis lung carcinoma model was 
used. Following anesthesia, mice were injected intravenously with 25 MBq of 99mTc-1-thio-D-glucose. Planar 
scintigraphy was performed 15 minutes later in a matrix of 512?512 pixels for 5 min. Results: when measuring the 
radioactivity of normal and malignant cells after incubation with 99mTc-1-thio-D-glucose, it was found that the 
radioactivity of malignant cells was higher than that of normal cells. The mean values of radioactivity levels in normal 
and malignant cells were 0.3 ± 0.15 MBq and 1.07 ± 0.6 MBq, respectively. All examined animals had increased 
accumulation of 99mTc-1-thio-D-glucose at the tumor site. The accumulation of 99mTc-1-thio-D-glucose in the tumor was 
on average twice as high as compared to the symmetric region. Conclusion: The present study demonstrated that 99mTc-1-
thio-D-glucose is a prospective radiopharmaceutical for cancer visualization. In addition, high accumulation of 99mTc-1-
thio-D-glucose in the culture of cancer cells and in tumor tissue of animals demonstrates tumor tropism of the 
radiopharmaceutical. 
INTRODUCTION 
Nuclear medicine techniques have become an indispensable tool for the diagnosis, treatment planning and 
management of cancer patients [1, 2]. Currently, there is a continuous search for new, more specific and efficient 
diagnostic and therapeutic radiopharmaceuticals. At the same time, the development of nuclear medicine imaging 
technologies in Russia is still far behind the world level. It is estimated that the demand for radiopharmaceuticals in 
Russia is satisfied by no more than 1–3%. A variety of positron-emitting nuclides is currently utilized to detect 
tumors and metastases as well as to monitor treatment response. The most commonly used PET radiopharmaceutical 
is a derivative of glucose, namely 2-(18F) fluoro-2-deoxy-glucose (18F-FDG) [3]. Despite the high diagnostic value 
of 18F-FDG-PET, the widespread use of this imaging modality in Russia is limited because of its high cost and lack 
of PET centers. In spite of advances in PET technologies worldwide, a large number of nuclear medicine 
laboratories in Russia are still equipped with gamma cameras. There are more than 200 SPECT (single photon 
emission computed tomography) centers in Russia. The most frequently used radionuclide for SPECT is technetium-
99m, therefore, it seems relevant to develop innovative radiopharmaceuticals for molecular imaging based on 
technetium-99m-labeled glucose derivatives [4–6]. The main advantage of radiotracers based on technetium-99m-
labeled glucose derivatives is the ability to image different tumor types using a gamma camera, thus significantly 
reducing the cost of the diagnostic procedure.  
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FIGURE 1. Chemical structure of 99mTc-1-thio-D-glucose 
 
A new tumor seeking agent, 99mTc-labeled 1-thio-D-glucose, is one of these radiotracers (Fig. 1). It was 
developed at the Polytechnic University and Cancer Research Institute (Tomsk, Russia). It is currently under 
preclinical safety testing at the Tomsk Cancer Research Institute. Thus, the purpose of the present study was to 
evaluate the potential utility of 99mTc-1-thio-D-glucose for tumor tissue imaging in animals. 
MATERIALS AND METHODS 
The radiopharmaceutical (99mTc-1-thio-D-glucose) was prepared from the reagent (lyophilizate) by adding 4 ml 
of sodium pertechnetate (99mTc). The composition of reagent (lyophilizate) was a solution of 1-thio-D-glucose in the 
presence of tin (II) chloride dihydrate (SnCl2 · 2H2O). After adding the reagent into a sterile vial, 99mTc sodium 
pertechnetate solution was incubated for 30 min at room temperature. The finished solution was a clear, colorless 
liquid. Description of the radiopharmaceutical: clear liquid, pH from 4.0 to 8.0 (6 ± 2); radiochemical impurity was 
not more than 8%. Radionuclide impurities: 99Mo—no more than 2?10–3%, others—no more than 1?10–4%. The 
concentration of sodium chloride ranged from 8.0 to 10.0 mg/ml. The content of the derivative of 1-thio-D-glucose 
was not more than 0.625 mg / ml. The content of tin dichloride dehydrate was 0.044–0.052 mg / ml. Gamma 
spectrum 99mTc 1-thio-D-glucose had a characteristic line with the energy of 0.140 MeV. 
The potential utility of 99mTc-1-thio-D-glucose for tumor imaging was studied in vitro and in vivo models. In 
vitro studies, the cell cultures from normal (Chinese hamster ovary (CHO) cells) and cancer tissues (MCF 7-human 
breast adenocarcinoma cell line) were used. To evaluate the uptake of 99mTc-1-thio-D-glucose in normal and tumor 
tissue cells, 25 MBq in 200 ?L of technetium-99m-labeled glucose derivative was added to vials with 
3 000 000 cells/ml, 5 vials for each cell culture. The vials with cells were then incubated for 30 minutes at room 
temperature with periodic gentle shaking to avoid cell adhesion. After completion of incubation, the vials were 
centrifuged at 300 rpm for 5 min. After sedimentation, the supernatant was removed carefully and the radioactivity 
measurement of the sediment and supernatant was made. Thereafter, the cells were washed three times by adding 
1 ml of buffer to each vial and centrifugation vials. PBS + 1% BCA were used as a buffer. 
The radioactivity in the sediment and supernatant was measured after each washing. After the final cell washing, 
cell-labeling efficiency, a percentage of 99mTc-labeled 1-thio-D-glucose accumulation in normal and cancer tissue 
cells was measured. In addition, planar scintigraphic imaging of the culture plates with vials was performed. 
In vivo studies, the potential utility of 99mTc-labeled 1-thio-D-glucose for tumor visualization was studied using 
the intramuscularly implanted solid Lewis lung carcinoma model in C57BL/6J mice (Bank of Cell Lines, NN 
Blokhin Russian Cancer Research Center, Moscow). A total of 40 male and female mice, weighing 30 ± 5 g and 
12 weeks of age, were used. The tumor size was 2 ± 0.2 cm3. The acquisition, care and housing of laboratory 
animals were in compliance with federal and local laws and regulations, as well as with ethical and legal principles 
of the European Convention for the Protection of Vertebrate Animals (Strasbourg, 1986). Mice were anesthetized by 
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inhalation of ethyl ether. To study the 99mTc-labeled 1-thio-D-glucose accumulation in the body of C57BL/6J 
mice bearing Lewis lung carcinoma, the radiotracer was injected intravenously in diagnostic dose after anesthesia. 
Whole-body gamma scintigraphy using SiemensE.Cam 180 gamma camera was performed 10–15 min after 
intravenous injection of the radiotracer. We used the high-resolution, low-energy collimators for140keV energy. The 
mice were placed with their ventral surface to the gamma camera detector so that the imaging field of view could 
encompass the whole body of the animal. Each image was acquired for 5 min. About 500,000 counts were recorded 
in each image with matrix size of 256?256 pixels. Radioactivity in regions of interest drawn in various organs of the 
mice and in tumor tissue was measured. Statistical analysis was performed using E.soft Software Version 5.5 
(Siemens). 
RESULTS 
The radioactivity in normal and tumor tissue cells after the final washing was measured using a gamma counter. 
The mean radioactivity levels in normal and tumor tissue cells after the final washing were 0.3 ± 0.15 MBq and 
1.07 ± 0.6 MBq, respectively. Thus, the 99mTc-labeled 1-thio-D-glucos uptake in cancer cells (MCF 7) was 3.5 times 
higher than that in normal tissue cells (CHO). Planar scintigraphic images of plates with culture vials showed more 
intense radiotracer accumulation in cancer tissue cells (Fig. 2). 
Planar scintigraphy was performed on tumor-bearing mice 10–15 min after intravenous injection of 25 MBq of 
99mTc-labeled 1-thio-D-glucos. Tumor was visualized in all mice. Most scintigraphic images demonstrated the 
tumor as a site of extremely high radiotracer uptake with clear contours. The uptake of the radiotracer in the tumor 
was frequently heterogeneous, with different intensity (Fig. 3). 
The changes in 99mTc-labeled 1-thio-D-glucos accumulation in the tumor after intravenous injection are 
demonstrated in Fig. 4. It should be noted that the maximum concentration of the 99mTc-labeled 1-thio-D-glucos in 
the tumor is recorded through 2 hours following intravenous administration. 
The images obtained showed that the mean radiotracer uptake intensity in the tumor was 2665.8 ± 431 counts, 
while in the symmetrical tissue it was 878.3 ± 134 counts. The relative 99mTc-labeled 1-thio-D-glucos uptake in the 
tumor was higher by 308.9 ± 94% than that in the symmetrical tissue. The percentage of the radiotracer tumor 
uptake from the total injected radiotracer dose was calculated. At 10-15 minutes after intravenous injection, the 
percentage of 99mTc-labeled 1-thio-D-glucos uptake in the tumor appeared to be 8.14% of the total injected 
radiotracer dose. Thus, the use of 99mTc-labeled 1-thio-D-glucos radiotracer for tumor imaging by single photon 
emission scintigraphy allowed tumor imaging in 100% of the laboratory mice. 
 
  
FIGURE 2. Scintigraphic imaging of culture plates containing 
cancer cells (1) and normal tissue cells (2) after incubation 
with 99mTc-labeled 1-thio-D-glucos and 3-time washing 
FIGURE 3. Scintigraphic image of tumor-bearing mice at 
15 min after intravenous injection of 99mTc-labeled 1-thio-D-
glucos. There is an extremely high radiotracer uptake in the 
tumor of the right femur (1) 
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FIGURE 4. The dynamics of 99mTc-labeled 1-thio-D-glucos accumulation in tumors in mice after intravenous 
administration. The maximum concentration of the 99mTc-labeled 1-thio-D-glucos  
in the tumor is recorded through 2 hours following intravenous injection 
 
CONCLUSION 
The results from this study indicate that 99mTc-labeled 1-thio-D-glucos, a new tumor-seeking agent based on 
technetium-99m-labeled glucose derivative, is a potentially useful tracer for tumor tissue imaging in the laboratory 
animals. Moreover, in vitro studies demonstrate highly selective accumulation of this radiotracer. The 99mTc-labeled 
1-thio-D-glucos uptake in tumor tissue cells was 3 times higher than that in normal tissue cells. However, further 
pre-clinical studies of 99mTc-labeled 1-thio-D-glucos are necessary to investigate its pharmacokinetics and safety. 
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